Abstract
Background
Q.Clear is a Bayesian penalized likelihood (BPL) reconstruction algorithm that presents improvements in signal-to-noise ratio (SNR) in clinical positron emission tomography (PET) scans. Brain studies in research require a reconstruction that provides a good spatial resolution and accentuates contrast features however, filtered back-projection (FBP) reconstruction is not available on GE SIGNA PET-Magnetic Resonance (PET-MR) and studies have been reconstructed with an ordered subset expectation maximization (OSEM) algorithm. This study aims to propose a strategy to approximate brain PET quantitative outcomes obtained from images reconstructed with Q.Clear versus traditional FBP and OSEM.
Methods
Contrast recovery and background variability were investigated with the National Electrical Manufacturers Association (NEMA) Image Quality (IQ) phantom. Resolution, axial uniformity and SNR were investigated using the Hoffman phantom. Both phantoms were scanned on a Siemens Biograph 6 TruePoint PET-Computed Tomography (CT) and a General Electric SIGNA PET-MR, for FBP, OSEM and Q.Clear. Differences between the metrics obtained with Q.Clear with different β values and FBP obtained on the PET-CT were determined.
Results
For in plane and axial resolution, Q.Clear with low β values presented the best results, whereas for SNR Q.Clear with higher β gave the best results. The uniformity results are greatly impacted by the β value, where β < 600 can yield worse uniformity results compared with the FBP reconstruction.
Conclusion
This study shows that Q.Clear improves contrast recovery and provides better resolution and SNR, in comparison to OSEM, on the PET-MR. When using low β values, Q.Clear can provide similar results to the ones obtained with traditional FBP reconstruction, suggesting it can be used for quantitative brain PET kinetic modelling studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Hammersmith Hospital, Invicro, Centre for Imaging Sciences, London, United Kingdom (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); University of Edinburgh, Edinburgh Imaging, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 Hammersmith Hospital, Invicro, Centre for Imaging Sciences, London, United Kingdom (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923)
3 University of Edinburgh, Edinburgh Imaging, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)